6Mok CC, Tong KH, To CH, et al. Tacrolimus for induction therapy of diffuse p - roliferate Ⅳ lupus nephritis: an openlabeled pilot study. Kidney Int,2005,68(2) :813.
7Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down -regulation of the T cell costimulatory molecule CD40 ligand: an openlabel trial. Arthritis Rheum,2005,52(2) :501 -513.
8Vigna - Perez M, Hernandez - Castro B, Paredes - Saharopulos O, et al. Clinical and immunological effects of Rituximab in patientswith lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther,2006,8 ( 3 ) : R83.
9Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 ( antiCD40 ligand antibody) imp roves serologic activity and decreases hematuria in patientswith proliferative lupus glomerulonephritis. Arthritis Rheum ,2003,48:719 - 727.
10Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transp lantation for systemic lupus erythematosus. JAMA ,2006,295 ( 5 ) :527.
